With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive ...

Key Takeaways Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations.

The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model ...

To help affected families and communities, Abbott and Abbott Fund are working with our longstanding disaster relief partner ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

a leader in performance nutrition products, was also acquired. In 2006, Abbott acquired Guidant, a leader in coronary and vascular products, and Kos Pharmaceuticals, a speciality pharma company ...

The medical nutrition market has grown significantly over the past few years, driven by rising health awareness, an aging population, and the increasing prevalence of chronic diseases. Understanding ...

The company, along with rival Abbott Laboratories, is defending more than 1,000 lawsuits that stand to potentially cost them ...